Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination.
Ioana AndreicaArturo Blazquez-NavarroJan SokolarMoritz AnftUta KiltzStephanie PfaenderElena Vidal BlancoTimm WesthoffNina BabelUlrik StervboXenofon BaraliakosPublished in: RMD open (2022)
Even after insufficient seroconversion for neutralising antibodies and IgG against SARS-CoV-2 spike-protein in patients with AIRDs on different medications, a second vaccination covered almost all patients regardless of DMARDs therapy, with better outcomes in those on IL-17i. However, no difference of bDMARD/tsDMARD or csDMARD therapy was found on the cellular immune response.
Keyphrases
- sars cov
- immune response
- end stage renal disease
- coronavirus disease
- newly diagnosed
- ejection fraction
- rheumatoid arthritis
- multiple sclerosis
- respiratory syndrome coronavirus
- prognostic factors
- rheumatoid arthritis patients
- peritoneal dialysis
- oxidative stress
- type diabetes
- stem cells
- inflammatory response
- small molecule
- drug induced
- systemic lupus erythematosus
- patient reported
- protein protein